Prana Biotechnology Ltd. (NASDAQ:PRAN)’s share price gapped up prior to trading on Friday . The stock had previously closed at $4.48, but opened at $4.50. Prana Biotechnology shares last traded at $4.60, with a volume of 14,196 shares changing hands.

Separately, Zacks Investment Research upgraded Prana Biotechnology from a “sell” rating to a “hold” rating in a report on Saturday, June 18th.

The firm’s market cap is $6.82 million. The firm’s 50-day moving average price is $4.61 and its 200 day moving average price is $3.73.

Prana Biotechnology Limited (Prana) is an Australia-based development stage medical biotechnology Company. The Company is engaged in commercializing research into Alzheimer’s disease, Huntington disease and other major age-related degenerative disorders. The Company’s lead drug candidate, PBT2 is being developed for the treatment of Alzheimer’s and Huntington’s diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.